Cognition Therapeutics, Inc. appointed John Doyle as Chief Financial Officer. Doyle was most recently CFO of 4D Pharma Plc, and previously was SVP and CFO of Chiasma Inc.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.015 USD | +3.33% | 0.00% | +8.11% |
07/06 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
29/05 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.11% | 7.81Cr | |
+18.07% | 12TCr | |
+13.26% | 11TCr | |
-7.28% | 2.42TCr | |
+1.92% | 2.28TCr | |
-10.79% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.25% | 1.64TCr | |
+0.76% | 1.36TCr | |
+26.35% | 1.17TCr |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Appoints John Doyle as Chief Financial Officer